Cybin

Cybin, Inc. is an ethical biopharmaceutical company engaged in the development of therapeutics for patients to address a multitude of mental health issues. It is focused on progressing psychedelics to therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches, and treatment regimens for mental health disorders. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

TORONTO--(BUSINESS WIRE)--Cybin Announces FDA Investigational New Drug Approval for Phase 2 Clinical Trial for Frontline Clinicians Experiencing COVID-Related Distress

Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for a Co-Funded Phase 2 Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Distress

TORONTO--(BUSINESS WIRE)--Cybin to Participate in the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, 2021

Cybin to Participate in the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, 2021

Psychedelic therapy company, Cybin Inc. (NEO: CYBN) (NYSE:CYBN), recently announced it was awarded a grant for the first psychedelic treatment clinic at New York City's Lenox Hill Hospital with which it will provide care to marginalized and underserved communities on Manhattan's Upper East Side.  “Lenox Hill Hospital is excited by the potential of these modalities for the treatment of previously intractable conditions such as severe depression, chronic PTSD, and OCD,” said Dr. David Roane, chairman of psychiatry at Lenox Hill Hospital.

NY's Lenox Hill Hospital With Cybin-Awarded Grant Will Provide Psychedelic Therapy To City's Underserved

TORONTO--(BUSINESS WIRE)--Cybin Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital to Benefit Underserved Communities

Cybin Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital to Benefit Underserved Communities

Cybin, Inc. (CYBN) CEO Doug Drysdale on Q2 2022 Results - Earnings Call Transcript

Toronto-based, Cybin Inc. (NEO: CYBN) (NYSE: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics,” reported its unaudited financial results on Monday for the second quarter ended September 30, 2021. Second-Quarter Financial Highlights

Cybin Reports Q2 Financial Results And Latest Business Highlights

TORONTO--(BUSINESS WIRE)--Cybin Inc. Reports its Second Quarter Financial Results and Recent Business Highlights

Cybin Inc. Reports its Second Quarter Financial Results and Recent Business Highlights

This article was originally published on Psychedelic Spotlight and appears here with permission. "Something that people used to speak about only in whispers is now standard policy," says the psychedelics researcher, with 20 years of experience, in a wide-ranging Q&A.

Can The Psychedelics Boom Go Bust? A Conversation With Cybin Chief Clinical Officer Dr. Alex Belser

TORONTO--(BUSINESS WIRE)--Cybin to Present at the Jefferies London Healthcare Conference

Cybin to Present at the Jefferies London Healthcare Conference

TORONTO--(BUSINESS WIRE)--Cybin to Announce Second Quarter FY2021 Financial Results and Business Update on November 15, 2021

Cybin to Announce Second Quarter FY2021 Financial Results and Business Update on November 15, 2021

Cybin Inc (NYSE: CYBN), a Toronto-based biotechnology company focused on utilizing psychedelic drugs as an alternative to traditional psychiatric drugs, announced positive pre-clinical data, indicating that its drug, CYB003 showed strong signs of cognitive improvement in patients with Major Depressive Disorder (MDD).  Cybin chemically engineered and developed CYB003 to address some of the shortcomings of oral psilocybin as a treatment for mental health, including slow onset, high variability and short duration of action.

Cybin Announces Positive Data Showing Effectiveness of Psilocybin To Treat Depression

Positive pre-clinical data for CYB003 isn't nearly as exciting as investors hoped it would be.

Why Cybin Stock Is Down on Monday

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today announced positive CYB003 pre-clinical findings that demonstrate multiple advantages for its newly developed novel deuterated psilocybin analog over oral psilocybin for the treatment of mental health. “Multiple academic studies have shown that psilocybin may have the potential to revolutionize mental healthcar

Cybin Announces Positive CYB003 Data Demonstrating Significant Advantages Over Oral Psilocybin for Treatment of Mental Health

Cybin Inc. (NYSE:CYBN) a company developing novel psychedelic compounds for therapeutic use, has received a Schedule I manufacturing license from the U.S. Drug Enforcement Agency (DEA). The DEA license is a federal requirement for any investigators intending to study, produce or analyze Schedule I substances.

Cybin Gets DEA License To Work With Scheduled Psychedelic Molecules

TORONTO--(BUSINESS WIRE)--Cybin Granted DEA Schedule I Manufacturing License

Cybin Granted DEA Schedule I Manufacturing License

TORONTO--(BUSINESS WIRE)--Cybin Hosting Research and Development Briefing on November 8, 2021

Cybin Hosting Research and Development Briefing on November 8, 2021

TORONTO--(BUSINESS WIRE)--Cybin Announces Launch of EMBARK Psychedelic Facilitator Training Program

Cybin Announces Launch of EMBARK Psychedelic Facilitator Training Program

TORONTO--(BUSINESS WIRE)--Cybin Announces FDA Investigational New Drug Authorization of Cybin's Sponsored Feasibility Study using Kernel Flow Technology

News for Cybin Stock (CYBN)